Cell division is governed by a biochemical oscillator built from cyclin-dependent kinases (CDKs) and their cyclin regulatory subunits, opposed by CDK inhibitors (CKIs) and checkpoint proteins. The G1/S restriction point — the irreversible commitment to cell division — is the most universally targeted cellular decision in oncogenesis, disrupted in virtually every human cancer through one of several alternative mechanisms: CDK4 amplification, cyclin D1 overexpression, p16INK4a (CDKN2A) deletion, or RB1 loss. Understanding this pathway reveals why CDK4/6 inhibitors work and which biomarkers predict resistance.
During G1, anti-mitogenic signals maintain pRb in its hypophosphorylated, E2F-repressing state. Mitogenic signals (RAS, WNT, PI3K) induce cyclin D1 accumulation, which assembles with CDK4/CDK6 and is T-loop activated by CAK. CDK4/6–cyclin D initially phosphorylates pRb at Ser780, partially de-repressing E2F targets including cyclin E. CDK2–cyclin E then hyperphosphorylates pRb, completing E2F release and constituting the restriction point crossover. This bistable switch ensures division commitment is irreversible once crossed.
During G1, anti-mitogenic signals maintain pRb in its hypophosphorylated, E2F-repressing state. Mitogenic signals (RAS, WNT, PI3K) induce cyclin D1 accumulation, which assembles with CDK4/CDK6 and is T-loop activated by CAK. CDK4/6–cyclin D initially phosphorylates pRb at Ser780, partially de-repressing E2F targets including cyclin E. CDK2–cyclin E then hyperphosphorylates pRb, completing E2F release and constituting the restriction point crossover. This bistable switch ensures division commitment is irreversible once crossed.
Cell Cycle G1→S Transition
Cyclin D1 binds CDK4 or CDK6, partially activating the kinase. CAK (CDK7–cyclin H) phosphorylates CDK4 at Thr172 for full kinase activation. p21 and p27 act as assembly factors at this stage, not inhibitors.
Newly synthesised CDK2–cyclin E hyperphosphorylates pRb at Ser795/811/821, completely releasing all bound E2F transcription factors. This creates a positive feedback loop (E2F drives more cyclin E, more CDK2 activity, more pRb phosphorylation) that makes the commitment irreversible — the restriction point.
Released E2F1/2/3 transcriptionally activate the complete S-phase programme: cyclin A, PCNA, MCM2-7 helicase complex, RRM1/2, and DNA polymerase δ components. CDK2–cyclin A replaces CDK2–cyclin E to drive S-phase progression.
The cyclin D–CDK4/6–RB axis is altered through different mechanisms across cancer, including CDK4 or CCND1 amplification, CDKN2A loss and RB1 inactivation. CDK4/6 inhibitors have population- and regimen-specific evidence in hormone-receptor-positive, HER2-negative breast cancer. Resistance is heterogeneous and can involve RB1 loss, cyclin–CDK changes or alternative proliferative signalling; one prevalence estimate should not be applied across drugs and disease settings.
CDK4/6 inhibitors are the paradigm of cell cycle-targeted therapy and require an intact RB1 gene for efficacy. Abemaciclib has additional CDK2/CDK9 activity and may retain partial activity in some RB1-intact tumours with non-classic resistance. Emerging approaches include CDK2 inhibitors (targeting cyclin E–CDK2 after CDK4/6 inhibitor resistance) and tri-complex CDK inhibitors targeting CDK4/cyclin D specifically over other CDKs.
Why can RB1 loss reduce sensitivity to CDK4/6 inhibitors?
CDK4/6 inhibitors rely on functional pRb to restrain E2F and maintain G1 arrest. Biallelic RB1 loss removes that downstream effector and is a biologically strong resistance mechanism. Clinical interpretation still depends on how RB1 was assessed, clonality, disease setting and other cell-cycle alterations rather than the word 'loss' alone.
What is the restriction point and why is it cancer-relevant?
The restriction point is the G1 moment of irreversible commitment to cell division, defined by pRb hyperphosphorylation and complete E2F release. Before the restriction point, cells require sustained mitogenic signals; after it, they divide autonomously. Cancer cells bypass the restriction point constitutively through CDK4 amplification, cyclin D overexpression, CDKN2A loss, or RB1 inactivation.
How does p53 enforce the G1 checkpoint?
After DNA damage, ATM/CHK2-mediated p53 phosphorylation stabilises p53, which transcriptionally activates CDKN1A (encoding p21). p21 inhibits CDK2/cyclin E and CDK4/cyclin D complexes, preventing pRb phosphorylation and maintaining G1 arrest. This gives the cell time for DNA repair before committing to S phase — when replication would amplify any mutations.
Understand how tumor suppressor genes — including TP53, BRCA1, PTEN, and RB1 — act as the genome's brakes, and what happens when they are lost in cancer.
How CDK4/6 inhibitors block the G1/S restriction point by protecting pRb from phosphorylation, their clinical evidence in breast cancer, and resistance mechanisms including RB1 loss.
How CDKN2A encodes two structurally unrelated tumor suppressors from the same locus, simultaneously protecting the pRb and p53 pathways, and why its deletion is so devastating in cancer.
Learn how different types of gene mutations — point mutations, deletions, amplifications, and fusions — drive cancer and inherited disease, with real examples from TP53, KRAS, and BRCA1.
Apoptosis Regulators
Apoptosis — programmed cell death — is the cell's ultimate tumour-suppressive mechanism, eliminating cells with irrepara…
Tumor Suppressor Networks
Tumour suppressor genes encode proteins that actively restrain cell proliferation, promote DNA repair, or eliminate dama…
DNA Damage Response Genes
Every human cell sustains approximately 70,000 DNA damage events per day, ranging from base oxidations and replication e…
EGFR–KRAS–BRAF–MEK–ERK Signalling Pathway in Cancer
The EGFR signalling pathway converts extracellular EGF binding into intracellular proliferative and survival signals via…
PI3K/AKT/mTOR Signalling Pathway
The PI3K/AKT/mTOR pathway integrates growth-factor, nutrient and energy signals to regulate cell survival, growth and me…
RAS/MAPK Signalling Pathway
The RAS/RAF/MEK/ERK (MAPK) cascade is one of the most ancient and conserved proliferative signalling pathways in eukaryo…